☰

Kutlu G. Elpek, Ph.D. - Publications

Affiliations: 
2007 University of Louisville, Louisville, KY, United States 
Area:
Immunology
Tree Info Similar researchers PubMed Report error

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Hanson A, Elpek K, Duong E, Shallberg L, Fan M, Johnson C, Wallace M, Mabry GR, Sazinsky S, Pepper L, Shu CJ, Sathyanarayanan S, Zuerndorfer S, Simpson T, Gostissa M, et al. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. Plos One. 15: e0239595. PMID 32970735 DOI: 10.1371/journal.pone.0239595  0.376
2020 Shamah S, Elpek K, Ezell T, Fleury M, Gallo M, Gori J, Heller S, Inniss M, Langley M, Olinger G, Richardson C, Tran K, Sethi D, Sun D, Suri V. Abstract 6604: Drug responsive domain regulation of IL15-engineered T cells provides pharmacological control over antigen-independent cell expansion Immunology. DOI: 10.1158/1538-7445.Am2020-6604  0.399
2019 Tran K, Elpek K, Ezell T, Heller S, Inniss M, Kulkarni A, Li DJ, Olinger G, Ols M, Reardon C, Sun D, Kassum T, Briskin M, Richardson C, Suri V, et al. Abstract A220: Destabilizing domain technology facilitates exogenous regulation of IL15 and IL12 for adaptive T-cell therapy Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A220  0.466
2019 Ols M, Schebesta M, Brideau E, Elpek K, Fleury M, Gori J, Heller S, Li DJ, Primack B, Reardon C, Sethi D, Storer A, Sun D, Tran K, Weisman E, et al. Abstract LB-013: CAR-Ts armored with small molecule-regulated IL12 or CD40L cassettes for enhanced activity against solid tumors Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-013  0.515
2018 Richardson C, Elpek K, Ols M, Kassum T, Shamah S. Abstract 3580: Enhancing adoptive cell therapies through exogenous regulation Immunology. DOI: 10.1158/1538-7445.Am2018-3580  0.314
2017 Michaelson JS, Harvey C, Elpek K, Duong E, Shallberg L, Wallace M, Mabry R, Shu J, Deshpande A, Zi T, Sazinsky S, Apgar J, Mounho-Zamora B, Briskin M, Trehu E, et al. Abstract SY03-02: Preclinical assessment of JTX-2011, an agonist antibody targeting ICOS, supports evaluation in ICONIC clinical trial Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Sy03-02  0.477
2016 Elpek K, Harvey C, Duong E, Simpson T, Shu J, Shallberg L, Wallace M, Sathy S, Mabry R, Michaelson J, Briskin M. Abstract A059: Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A059  0.508
2016 Michaelson JS, Harvey CJ, Elpek KG, Duong E, Wallace M, Shu CJ, Sathyanarayanan S, Mabry R, Shallberg L, Zi T, Deshpande A, Sazinsky SL, Apgar J, Law D. Abstract 573: Preclinical evaluation of JTX-2011, an anti-ICOS agonist antibody Cancer Research. 76: 573-573. DOI: 10.1158/1538-7445.Am2016-573  0.448
2015 Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, Dehlink E, Shade KT, Anthony RM, Blumberg RS, Turley SJ, Fiebiger E. IgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses. Cell Reports. PMID 25753415 DOI: 10.1016/J.Celrep.2015.02.015  0.516
2015 Harvey C, Elpek K, Duong E, Simpson T, Shu CJ, Shallberg L, Wallace M, Sathyanarayanan S, Mabry R, Briskin M, Michaelson J, Gajewski TF. Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-O9  0.525
2014 Elpek KG, Cremasco V, Shen H, Harvey CJ, Wucherpfennig KW, Goldstein DR, Monach PA, Turley SJ. The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells. Cancer Immunology Research. 2: 655-67. PMID 24801837 DOI: 10.1158/2326-6066.Cir-13-0209  0.42
2014 Zhou P, Shaffer DR, Alvarez Arias DA, Nakazaki Y, Pos W, Torres AJ, Cremasco V, Dougan SK, Cowley GS, Elpek K, Brogdon J, Lamb J, Turley SJ, Ploegh HL, Root DE, et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature. 506: 52-7. PMID 24476824 DOI: 10.1038/Nature12988  0.423
2014 Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu S, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, et al. GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition Blood. 124: 3567-3567. DOI: 10.1182/Blood.V124.21.3567.3567  0.399
2013 Mingueneau M, Kreslavsky T, Gray D, Heng T, Cruse R, Ericson J, Bendall S, Spitzer MH, Nolan GP, Kobayashi K, von Boehmer H, Mathis D, Benoist C, Best AJ, ... ... Elpek K, et al. The transcriptional landscape of αβ T cell differentiation. Nature Immunology. 14: 619-32. PMID 23644507 DOI: 10.1038/Ni.2590  0.386
2012 Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, Franz B, Hess PR, Jakus Z, Kuligowski M, Fletcher AL, Elpek KG, Bellemare-Pelletier A, Sceats L, Reynoso ED, Gonzalez SF, Graham DB, et al. Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity. 37: 276-89. PMID 22884313 DOI: 10.1016/J.Immuni.2012.05.022  0.38
2012 Miller JC, Brown BD, Shay T, Gautier EL, Jojic V, Cohain A, Pandey G, Leboeuf M, Elpek KG, Helft J, Hashimoto D, Chow A, Price J, Greter M, Bogunovic M, et al. Deciphering the transcriptional network of the dendritic cell lineage. Nature Immunology. 13: 888-99. PMID 22797772 DOI: 10.1038/Ni.2370  0.392
2012 Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF, Elpek KG, Chang SK, Knoblich K, Hemler ME, Brenner MB, Carroll MC, Mooney DJ, Turley SJ. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nature Immunology. 13: 499-510. PMID 22466668 DOI: 10.1038/Ni.2262  0.387
2011 Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y, Wang W, Ren X, Zheng H, Kimmelman AC, Paik JH, Lim C, et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discovery. 1: 158-69. PMID 21984975 DOI: 10.1158/2159-8290.Cd-11-0031  0.361
2011 Lukacs-Kornek V, Malhotra D, Fletcher AL, Acton SE, Elpek KG, Tayalia P, Collier AR, Turley SJ. Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nature Immunology. 12: 1096-104. PMID 21926986 DOI: 10.1016/J.Niox.2012.04.032  0.41
2011 Elpek KG, Bellemare-Pelletier A, Malhotra D, Reynoso ED, Lukacs-Kornek V, DeKruyff RH, Turley SJ. Lymphoid organ-resident dendritic cells exhibit unique transcriptional fingerprints based on subset and site. Plos One. 6: e23921. PMID 21886840 DOI: 10.1371/Journal.Pone.0023921  0.356
2011 Takeda Y, Li Q, Kazarov AR, Epardaud M, Elpek K, Turley SJ, Hemler ME. Diminished metastasis in tetraspanin CD151-knockout mice. Blood. 118: 464-72. PMID 21536858 DOI: 10.1182/Blood-2010-08-302240  0.466
2010 Elpek KG, Rubinstein MP, Bellemare-Pelletier A, Goldrath AW, Turley SJ. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proceedings of the National Academy of Sciences of the United States of America. 107: 21647-52. PMID 21098276 DOI: 10.1073/Pnas.1012128107  0.438
2010 Turley SJ, Fletcher AL, Elpek KG. The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs. Nature Reviews. Immunology. 10: 813-25. PMID 21088682 DOI: 10.1038/Nri2886  0.462
2010 Sharma RK, Yolcu ES, Elpek KG, Shirwan H. Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy. Cancer Gene Therapy. 17: 730-41. PMID 20559332 DOI: 10.1038/Cgt.2010.29  0.667
2010 Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, Shirwan H. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Research. 70: 3945-54. PMID 20406989 DOI: 10.1158/0008-5472.Can-09-4480  0.728
2010 Elpek KG, Rubinstein MP, Bellemare-Pelletier A, Goldrath AW, Turley SJ. Abstract 3829: Chronic stimulation with IL-15/IL-15Rα complexes leads to NK cell dysfunction Cancer Research. 70: 3829-3829. DOI: 10.1158/1538-7445.Am10-3829  0.479
2010 Sharma RK, Schabowsky R, Srivastava AK, Yolcu ES, Elpek KG, Zhao H, Madireddi S, Shirwan H. Abstract 2416: SA-4-1BBL costimulatory ligand as an immune modulator and effective vehicle to deliver antigens into dendritic cells for the generation of robust therapeutic antitumor immune responses Cancer Research. 70: 2416-2416. DOI: 10.1158/1538-7445.Am10-2416  0.717
2010 Sharma RK, Yolcu ES, Elpek KG, Shirwan H. Abstract 1501: Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy Cancer Research. 70: 1501-1501. DOI: 10.1158/1538-7445.Am10-1501  0.633
2010 Sharma R, Schabowsky R, Srivastava A, Yolcu E, Elpek K, Zhao H, Madireddi S, Shirwan H. SA-4-1BBL Serves as an Immune Modulator as well as Vehicle to Deliver Antigens into Dendritic Cells in vivo for Generation of Robust Immunity for Eradication of Tumors Clinical Immunology. 135: S86. DOI: 10.1016/J.Clim.2010.03.258  0.629
2009 Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ, Mittler RS, Shirwan H. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine. 28: 512-22. PMID 19836479 DOI: 10.1016/J.Vaccine.2009.09.127  0.648
2009 Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Shirwan H. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Research. 69: 4319-26. PMID 19435920 DOI: 10.1158/0008-5472.Can-08-3141  0.712
2009 Reynoso ED, Elpek KG, Francisco L, Bronson R, Bellemare-Pelletier A, Sharpe AH, Freeman GJ, Turley SJ. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. Journal of Immunology (Baltimore, Md. : 1950). 182: 2102-12. PMID 19201863 DOI: 10.4049/Jimmunol.0802769  0.387
2008 Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, Hamerman JA, Goldrath AW, Turley SJ. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Research. 68: 2972-83. PMID 18413767 DOI: 10.1158/0008-5472.Can-08-0045  0.445
2008 Sharma R, Elpek K, Yolcu E, Schabowsky R, Zhao H, Bandura-Morgon L, Shirwan H. Su.60. A Novel Vaccine Concept for Treatment of Cervical Cancer Clinical Immunology. 127: S143-S144. DOI: 10.1016/J.Clim.2008.03.411  0.589
2007 Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. Journal of Immunology (Baltimore, Md. : 1950). 179: 7295-304. PMID 18025172 DOI: 10.4049/Jimmunol.179.11.7295  0.7
2007 Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. Journal of Immunology (Baltimore, Md. : 1950). 178: 6840-8. PMID 17513732 DOI: 10.4049/Jimmunol.178.11.6840  0.688
2007 Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunology, Immunotherapy : Cii. 56: 997-1007. PMID 17146630 DOI: 10.1007/S00262-006-0247-2  0.596
2005 Köksoy S, Elpek KG, Yolcu ES, Shirwan H. Tolerance to rat heart grafts induced by intrathymic immunomodulation is mediated by indirect recognition primed CD4+CD25+ Treg cells. Transplantation. 79: 1492-7. PMID 15940037 DOI: 10.1097/01.Tp.0000159870.01567.02  0.634
Show low-probability matches.